Supplementary Material for: Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy

  • Hala Yamout (Creator)
  • Vlado Perkovic (Creator)
  • Melanie Davies (Creator)
  • Vincent Woo (Creator)
  • Dick de Zeeuw (Creator)
  • Cristiana Mayer (Creator)
  • Ujjwala Vijapurkar (Creator)
  • Irina Kline (Creator)
  • Keith Usiskin (Creator)
  • Gary Meininger (Creator)
  • George Bakris (Contributor)



Background/Aims: Some sodium glucose co-transporter 2 (SGLT2) inhibitors are approved for the treatment of patients with type 2 diabetes mellitus (T2DM) with an estimated glomerular filtration rate (eGFR) of ≥45 ml/min/1.73 m2. The efficacy and safety of canagliflozin, an approved SGLT2 inhibitor, was evaluated in patients with stage 3 chronic kidney disease (CKD; eGFR ≥30 to
Date made available17-Jul-2014
PublisherKarger Publishers

Keywords on Datasets

  • Diabetes
  • Kidney
  • Nephropathy
  • Hypertension

Cite this